18.23

2.57% -0.54

Moonlake Immunotherapeutics (MLTX)

Overview News Price History Option Chain Financials Why MLTX Down? Discussions Forecast

Moonlake Immunotherapeutics stock is traded at $18.23, with a volume of 1.62M. It is down -2.57% in the last 24 hours and up +15.31% over the past month. MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.

Previous Close:

$18.77

Open:

$18.765

24h Volume:

1.62M

Relative Volume:

0.75

Market Cap:

$1.29B

Revenue:

Net Income/Loss:

$-145.21M

P/E Ratio:

-7.9261

EPS:

-2.3

Net Cash Flow:

$-140.12M

1W Performance:

+15.97%

1M Performance:

+15.31%

6M Performance:

-67.28%

1Y Performance:

-56.80%

1-Day Range:

$17.80

$19.49

1-Week Range:

$15.78

$19.49

52-Week Range:

$5.95

$62.75

Moonlake Immunotherapeutics Stock (MLTX) Company Profile

Name

Moonlake Immunotherapeutics

Sector

Healthcare (1117)

Industry

Biotechnology (619)

Phone

41 41 510 8022

Address

DORFSTRASSE 29, ZUG

Employee

100

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

MLTX's Discussions on Twitter

Compare MLTX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MLTX Moonlake Immunotherapeutics	18.22	1.33B	0	-145.21M	-140.12M	-2.30
VRTX Vertex Pharmaceuticals Inc	485.71	121.15B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	785.50	82.43B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	828.96	52.25B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	330.68	44.59B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	366.48	40.07B	4.98B	69.60M	525.67M	0.5198

Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-15-26	Downgrade	Goldman	Neutral → Sell
Jan-09-26	Upgrade	BTIG Research	Neutral → Buy
Nov-03-25	Upgrade	H.C. Wainwright	Neutral → Buy
Oct-02-25	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-01-25	Downgrade	Goldman	Buy → Neutral
Sep-30-25	Downgrade	Citigroup	Buy → Neutral
Sep-30-25	Downgrade	Wolfe Research	Outperform → Underperform
Sep-29-25	Downgrade	BTIG Research	Buy → Neutral
Sep-29-25	Downgrade	Jefferies	Buy → Hold
Sep-29-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Sep-29-25	Downgrade	Stifel	Buy → Hold
Jul-28-25	Initiated	Rothschild & Co Redburn	Neutral
May-19-25	Upgrade	Wolfe Research	Peer Perform → Outperform
Mar-18-25	Initiated	RBC Capital Mkts	Outperform
Jan-17-25	Upgrade	Goldman	Neutral → Buy
Nov-05-24	Resumed	Wedbush	Outperform
Aug-26-24	Downgrade	Wolfe Research	Outperform → Peer Perform
Jun-25-24	Initiated	Oppenheimer	Outperform
Apr-02-24	Initiated	Goldman	Neutral
Feb-15-24	Initiated	Wolfe Research	Outperform
Dec-08-23	Initiated	Citigroup	Buy
Nov-02-23	Initiated	Stifel	Buy
Sep-14-23	Downgrade	Bryan Garnier	Buy → Neutral
Aug-31-23	Initiated	Needham	Buy
Jun-15-23	Initiated	Barclays	Equal Weight
May-01-23	Initiated	Guggenheim	Buy
Mar-22-23	Initiated	Wedbush	Outperform
Mar-09-23	Initiated	BTIG Research	Buy
Feb-14-23	Initiated	Cantor Fitzgerald	Overweight
Feb-02-23	Initiated	Bryan Garnier	Buy
Nov-11-22	Initiated	Jefferies	Buy
Aug-25-22	Initiated	SVB Leerink	Outperform
Jul-21-22	Initiated	H.C. Wainwright	Buy
Jul-07-22	Initiated	Cowen	Outperform

View All

Moonlake Immunotherapeutics Stock (MLTX) Latest News

10:23 AM